Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease

Mar 16, 2004·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Xiaoming ShuaiGuobin Wang

Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro

Mar 15, 2002·Pancreas·Kenzo KanekoTooru Shimosegawa

Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer

Sep 1, 2005·Annals of Surgical Oncology·Robert J CanterDouglas L Fraker

Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease

Abstract

References

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide

Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo

Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.

Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma

Expression of c-erbB-2 in human pancreatic adenocarcinomas

Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Restenosis after successful coronary angioplasty. Pathophysiology and prevention.

Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients.

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Methylthioadenosine phosphorylase in human breast cancer

A review of the proliferative behaviour, morphology and phenotypes of vascular smooth muscle

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

The state of the art in antisense research

Does antisense exist?

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor

Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification

Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression

Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury

Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts.

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

Antisense strategies and therapeutic applications

Towards genomic drug therapy with antisense oligonucleotides

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Effects of synthetic oligonucleotides on human complement and coagulation

Selecting effective antisense reagents on combinatorial oligonucleotide arrays

Advances in understanding the pharmacological properties of antisense oligonucleotides

Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide

Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A

The bcl-2 family of proteins

Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells

Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

Potent and selective inhibition of gene expression by an antisense heptanucleotide

Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu

Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts

Antisense strategies for the treatment of hematological malignancies and solid tumors

Antisense comes of age

Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro

Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle

Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects

Fomivirsen

Citations

Effects of cyclin D1 antisense oligodeoxyneucleotides on the growth and expression of G1 phase regulators in gastric carcinoma cells

Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides

Antisense Tcf inhibits the neoplastic growth of liver cancer cells

Human papillomavirus therapy for the prevention and treatment of cervical cancer

Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells

Antisense therapeutics: from theory to clinical practice

Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers

Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro

Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer

Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers

STAT proteins: novel molecular targets for cancer drug discovery

HER2/neu antisense targeting of human breast carcinoma

Tailor-made core-shell nanospheres for antisense oligonucleotide delivery: IV. Adsorption/release behaviour

Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase

Core-shell nanospheres for oligonucleotide delivery. V: adsorption/release behavior of 'stealth' nanospheres

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

Related Papers

Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists

The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion model

Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene

A yeast chemical genetic screen identifies inhibitors of human telomerase.

Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers